Lung health management platform Aluna has completed a $15.3 million (£12.4 million) Series B round of financing.
The funds will help Aluna grow its solution among doctors and patients managing asthma, cystic fibrosis and COPD.
Aluna’s AI-enabled respiratory management platform enables patients to transmit data to their doctor by blowing into their innovative spirometer daily.
The patient-facing app allows patients to collect symptoms, medication, activity and environmental factors.
A proprietary ML algorithms help medical teams identify respiratory problems and take corrective action to keep their health under control.
Aluna CEO and co-founder, Charvi Shetty, said
“As two of many asthma sufferers, my co-founder and I set out from day one to build a platform that would not only keep patients healthy, but also help providers provide the best possible care.
“Our growth will enable asthma, COPD and other chronic respiratory patients and their providers to work more effectively together and prevent attacks before they happen.
“Down the road, we hope to leverage our lung health data to revolutionise respiratory care.”
Around one in thirteen Americans has asthma, and the number is rising due to environmental factors.
Asthma attacks lead to more than one million emergency room visits each year, according to the American College of Asthma, Allergy & Immunology.
Aluna’s FDA-cleared spirometer device and easy-to-use app allows allergists, pulmonologists and other providers to offer care early and avoid hospital visits for the patient.
Antonio Rodriguez, General Partner at lead investor Matrix, said:
“Aluna is paving the way for the entire healthcare system to discover the ways technology can change the lives of asthmatics.
“By combining the gold standard for measuring lung function with an innovative device, the cloud, and their proprietary algorithms, the company is giving superpowers to clinicians who can more effectively treat patients.”
Aluna COO, Jason Hochman, added:
“Preventing unnecessary emergency visits is something patients, doctors and insurance companies all want and Aluna is uniquely positioned to provide.
“As we head into 2023, we plan to grow Aluna’s product and its scale with this funding and the support of our partners.”